Brief: CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025
21/07/2025 16:52
July 21 (Reuters) - CytoMed Therapeutics Ltd F98.F: UPDATE ON CLINICAL TRIAL MILESTONE - CYTOMED THERAPEUTICS ACHIEVES COMPLETION OF DOSE LEVEL 1 OF ITS ANGELICA TRIAL, AND PROCEEDING TO DOSE LEVEL 2 IN PATIENTS WITH ADVANCED SOLID TUMORS OR HAEMATOLOGICAL MALIGNANCIES CYTOMED THERAPEUTICS LTD - TO START DOSE LEVEL 2 IN ANGELICA TRIAL Q3 2025 Source text: ID:nGNX7jls4Z Further company coverage: F98.F ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on CytoMed Therapeutics
See all newsBrief: Cytomed Therapeutics Limited Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brief: Cytomed Therapeutics Refutes "Misleading" Claims & Reaffirms Clinical Progress
Brief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025
Brief: Cytomed Therapeutics Ltd Files For Mixed Shelf Of Up To $50 Million